These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 18771751)
1. Reflux inhibitors: a new approach for GERD? Boeckxstaens GE Curr Opin Pharmacol; 2008 Dec; 8(6):685-9. PubMed ID: 18771751 [TBL] [Abstract][Full Text] [Related]
2. Treatment of gastro-esophageal reflux disease: the new kids to block. Blondeau K Neurogastroenterol Motil; 2010 Aug; 22(8):836-40. PubMed ID: 20663054 [TBL] [Abstract][Full Text] [Related]
3. Novel treatments of GERD: focus on the lower esophageal sphincter. Lehmann A Eur Rev Med Pharmacol Sci; 2008 Aug; 12 Suppl 1():103-10. PubMed ID: 18924449 [TBL] [Abstract][Full Text] [Related]
4. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Beaumont H; Smout A; Aanen M; Rydholm H; Lei A; Lehmann A; Ruth M; Boeckxstaens G Aliment Pharmacol Ther; 2009 Nov; 30(9):937-46. PubMed ID: 19650825 [TBL] [Abstract][Full Text] [Related]
5. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors. Johnson DA; Levy BH Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445 [TBL] [Abstract][Full Text] [Related]
6. GABAB receptors as drug targets to treat gastroesophageal reflux disease. Lehmann A Pharmacol Ther; 2009 Jun; 122(3):239-45. PubMed ID: 19303900 [TBL] [Abstract][Full Text] [Related]
7. Medical treatment of GORD. Emerging therapeutic targets and concepts. Zerbib F Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):937-46. PubMed ID: 21126705 [TBL] [Abstract][Full Text] [Related]
9. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease. Tack J Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988 [TBL] [Abstract][Full Text] [Related]
10. New pharmacological agents for the treatment of gastroesophageal reflux disease. Vakil N Rev Gastroenterol Disord; 2008; 8(2):117-22. PubMed ID: 18641594 [TBL] [Abstract][Full Text] [Related]
11. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Beaumont H; Boeckxstaens GE Am J Gastroenterol; 2009 Jul; 104(7):1764-71. PubMed ID: 19491837 [TBL] [Abstract][Full Text] [Related]
12. Lesogaberan, a GABA(B) agonist for the potential treatment of gastroesophageal reflux disease. Bredenoord AJ IDrugs; 2009 Sep; 12(9):576-84. PubMed ID: 19697277 [TBL] [Abstract][Full Text] [Related]
13. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. Lehmann A; Antonsson M; Holmberg AA; Blackshaw LA; Brändén L; Bräuner-Osborne H; Christiansen B; Dent J; Elebring T; Jacobson BM; Jensen J; Mattsson JP; Nilsson K; Oja SS; Page AJ; Saransaari P; von Unge S J Pharmacol Exp Ther; 2009 Nov; 331(2):504-12. PubMed ID: 19648470 [TBL] [Abstract][Full Text] [Related]